How to Get Wegovy or Zepbound Covered by Employer Insurance in 2026: Prior Authorization, Formulary Exceptions, and the Exclusion Workarounds

Your doctor wrote the prescription. The pharmacy ran it through your insurance. The rejection came back in three characters: PA. Or worse — NDC not covered, no override available. Or the pharmacist quietly told you the cash price is $1,349 for 28 days and asked if you still wanted to fill it.

You are not the only one. In 2026, only about 36% of employer plans covered GLP-1 medications for weight loss, a number that has stayed roughly flat for two years and actually tightened on January 1, 2026 as several large plans dropped or narrowed the benefit. Coverage skews sharply by employer size — around 43% at firms with 5,000+ workers, closer to 16% at firms with 200 to 999 employees. And every plan that does cover it layers on prior authorization, step therapy, BMI thresholds, and reauthorization windows that make what looks like a covered drug into a documentation project.

There is still a clear playbook. It starts with a triage question most people skip — is this a plan exclusion or a prior authorization denial? — and branches from there into the documentation package that makes a PA succeed on the first pass, the sleep-apnea and cardiovascular indications that can bypass a weight-loss exclusion entirely, the formulary exception request, and the internal appeal that reverses roughly 60% of well-documented GLP-1 denials.

This is the single most important step, and most people go straight past it. A plan exclusion and a prior authorization denial look identical at the pharmacy counter and require completely different responses.

A plan exclusion means your employer's plan sponsor has carved anti-obesity medications out of the pharmacy benefit entirely. No amount of clinical documentation will get the drug covered as a weight-loss agent under that benefit. The exclusion has to be lifted at the employer level or the drug has to be prescribed under a non-excluded FDA indication.

A prior authorization denial means the drug is covered in principle but the plan wants documentation before it pays. Prior authorization denials are almost always fixable through documentation and appeal — nearly 88% of GLP-1 coverage that exists requires PA, and roughly 60% of well-documented appeals succeed.

Find out which one you are dealing with in three steps:

1. Read the Summary Plan Description (SPD) and the pharmacy formulary. Look for language like "anti-obesity medications," "weight-loss drugs," "medications for weight reduction," or "obesity treatment" in the excluded services section. Also check the formulary tier document for whether Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) appear at all.
2. Call the pharmacy benefit manager (PBM) at the number on your insurance card. Read the exact rejection code the pharmacy received. NDC-level exclusions ("not a covered benefit") are different from PA rejections ("prior authorization required"). Ask specifically: "Is this excluded from the plan, or is this a PA that I can submit?"
3. Ask HR benefits point blank. The scripted question: "Does the plan exclude anti-obesity medications from the pharmacy benefit, or are Wegovy and Zepbound covered with prior authorization?" HR sometimes cannot answer the second half but can always answer the first — the exclusion is a plan design choice they made.

Assume the PA will be reviewed by a clinical pharmacist who has 4 minutes to make a decision on your file. Your job is to hand them a package that maps directly to the plan's own criteria so approval is the path of least resistance.

The standard 2026 PA package for Wegovy or Zepbound weight-loss indication includes:

Two things to insist your prescriber include even if the PA form doesn't ask for them: prior weight measurements over the last 12 months (shows sustained obesity rather than acute weight gain) and a specific target percentage weight loss (5-10% is standard). Both make the file look complete on the initial review rather than pending an information request that will delay the decision by another two weeks.

This is where a lot of people who thought they were locked out get in.

Zepbound for obstructive sleep apnea. The FDA expanded tirzepatide (Zepbound) to include treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. When Zepbound is prescribed under the OSA indication with a sleep study documenting AHI in the moderate-to-severe range, and coded G47.33, many plans that exclude weight-loss drugs will cover it — because the plan excluded weight-loss drugs, not OSA treatment. The result (weight loss) is the same. The coverage door is different.

Wegovy for cardiovascular risk reduction. Semaglutide 2.4 mg (Wegovy) has an FDA indication for reducing the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight or obesity. Established CVD includes prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease. When the prescribing indication on the PA is CV risk reduction, coded appropriately (e.g., I25.10 for atherosclerotic heart disease, I63.9 for prior CVA, I73.9 for PAD), Wegovy is not being prescribed as a weight-loss drug at all — it is a cardiovascular therapy that has the side benefit of weight loss. This often falls outside a weight-loss exclusion.

Ozempic and Mounjaro for type 2 diabetes. Semaglutide (Ozempic) and tirzepatide (Mounjaro) are approved for type 2 diabetes. If your BMI qualifies and you have documented T2D or, in many plans, well-documented prediabetes with additional risk factors, the T2D indication is essentially universally covered. The problem people run into: the plan will cover Ozempic for T2D but not Wegovy for weight loss even though the active ingredient (semaglutide) is the same. The path when covered under T2D is fine; the path when the plan sees "chronic weight management" as the indication is different.

If the plan covers Wegovy or Zepbound but only after step therapy through cheaper alternatives (Contrave, Qsymia, or an older GLP-1 like liraglutide), or only at a higher cost-sharing tier, a formulary exception request is the mechanism to bypass the restriction.

Two variants:

• Non-formulary exception — the plan does not list the drug at all in its formulary. The prescriber submits a statement that formulary alternatives would not be as effective, would cause adverse reactions, or are contraindicated. Approval covers the drug at a specified tier.
• Tiering exception — the plan lists the drug but on a higher tier (specialty tier, typically 25-50% coinsurance). The prescriber submits a statement that lower-tier alternatives are not clinically appropriate. Approval moves the drug to a lower tier with lower cost sharing.

Timelines: 72 hours for a standard exception decision, 24 hours for expedited (when waiting could seriously jeopardize the patient's health). The prescriber, not the patient, files the request. If the prescriber's office says "we don't do those," escalate — most offices have a PA/exception team, and if yours truly doesn't, patient advocacy organizations like the Obesity Action Coalition can sometimes coach the prescriber's staff through it.

Roughly 60% of well-documented internal appeals for GLP-1 denials reverse. The pattern that works has six elements:

1. Quote the exact denial reason and address it line by line

Pull the denial letter or the pharmacy rejection code. If the plan said "BMI documentation insufficient," lead the appeal with the BMI history, measurement dates, and provider notes. If the plan said "step therapy not met," lead with the specific prior trials with dates, doses, and outcomes.

2. Include a clinical letter from the prescriber

Ideally 1 to 2 pages, on office letterhead. Structure: diagnosis with ICD-10 codes, relevant history and current status, prior treatment attempts and outcomes, clinical rationale for GLP-1 specifically (rather than a formulary alternative), specific FDA indication being treated, and a request for approval with the requested duration and dosing.

3. Attach the FDA prescribing information and any relevant clinical guidelines

Endocrine Society and American Association of Clinical Endocrinology guidelines on obesity pharmacotherapy support GLP-1 use as first-line for many patients. The American Heart Association supports semaglutide 2.4 mg for CV risk reduction. AASM guidelines on OSA support GLP-1 for obesity-related OSA. Citing recognized guidelines shifts the discussion from a plan's internal medical policy to a broader clinical standard.

4. Ask for a peer-to-peer review with a same-specialty reviewer

Bariatric medicine physician, endocrinologist, cardiologist, or sleep medicine specialist depending on the indication. Same-specialty reviewers reverse categorical denials in real-time conversations at much higher rates than internal PA reviewers.

5. Request the specific medical necessity criteria the plan used

You are entitled to the criteria. If the plan's internal PA rule is stricter than the FDA indication or the recognized clinical guideline, that gap is an argument point.

6. State the outcome you want and the deadline

Specific: "Approve Zepbound 7.5 mg weekly for 6 months per the treating team's request, with reauthorization at that point based on demonstrated clinical benefit." Copy your HR benefits contact. Send by fax and certified mail with return receipt.

If the internal appeal fails, the escalation path depends on the plan type:

Fully insured plans (ACA marketplace, small-group, individual)

You have the right to an independent external review by an accredited Independent Review Organization (IRO). The IRO's decision is binding on the insurer. Instructions come with the final internal denial letter, and the state Department of Insurance can help if the insurer stalls. External review is often the fastest path to a binding reversal for medical necessity denials.

Self-funded employer plans (most large-employer plans)

Self-funded plans governed by ERISA do not automatically go through external IRO review, though many voluntarily do. If yours does not, and the internal appeal is exhausted, file a complaint with the Department of Labor's Employee Benefits Security Administration (EBSA) at askebsa.dol.gov or 1-866-444-3272. EBSA advisors can often escalate the case with the plan informally.

State Department of Insurance complaint (fully insured only)

State insurance regulators require insurers to respond in writing, typically within 30-45 days. Filing during or after the internal appeal often accelerates resolution because the plan knows a regulator is watching.

Employer-level advocacy

For a self-funded plan, the ultimate lever is the plan sponsor — your employer. HR benefits committees do change plan design each year, and coordinated employee input during the plan-year comment window can move coverage decisions. This is a longer path than an appeal but the only one that lifts a true exclusion.

Do not stop the medication if you can help it. GLP-1 discontinuation frequently produces rapid weight regain and, for people on the drug for cardiovascular risk reduction or OSA, loss of the clinical benefit. Two bridge options are worth knowing:

• Manufacturer direct-to-consumer programs. Eli Lilly's LillyDirect offers Zepbound single-dose vials at roughly $349 to $499 per month depending on dose. Novo Nordisk's NovoCare offers Wegovy at similar pricing. Both require you to pay cash rather than run the fill through insurance for that month. If your appeal ultimately succeeds, some plans will retroactively reimburse cash payments during the appeal window; keep the receipts.
• Manufacturer patient assistance programs. Lilly Cares and Novo Nordisk Patient Assistance Program can provide free drug for patients with household income under a threshold (typically 400% FPL, roughly $62,600 for a single-person household in 2026) who have no insurance coverage for the drug. Application takes 2 to 4 weeks.

Avoid compounded semaglutide from unfamiliar telehealth sources. The FDA compounding shortage exemption ended in 2024-2025 and the legitimate compounded GLP-1 market has narrowed sharply. Off-the-radar compounded product has been associated with dosing errors and contamination.

If you use an HSA, GLP-1 medication prescribed for a diagnosed condition (obesity, T2D, OSA, CVD) is a qualified medical expense — HSA funds pay for it tax-free. Track your out-of-pocket spend, because it also counts toward your deductible and out-of-pocket max if you're eventually paying through insurance again.

List price for Wegovy or Zepbound is roughly $1,100 to $1,350 per month at retail. Even one year of unassisted retail pricing runs $13,000 to $16,000. That is why the coverage fight is worth having, and why the direct-to-consumer bridge programs at $349 to $499 per month are not a permanent solution for most households.

Three quick numbers to check before you conclude the drug is unaffordable:

• What is my true monthly out-of-pocket if PA is approved? If the plan places Wegovy on a specialty tier with 30% coinsurance, that could still be $300-$400 per month. Model that against your deductible status using our Plan Cost Calculator.
• What does the same GLP-1 cost across pharmacies? Prices vary significantly by pharmacy even for the same insurance. Check pricing before you fill using the Drug Cost Finder.
• Would switching plans at open enrollment matter? A different plan with GLP-1 coverage may be worth the premium delta. Use the Plan Cost Calculator to compare total cost of care under each option, and the ACA Subsidy Calculator if you would switch to a marketplace plan.

If you're using or considering an HSA-eligible plan, the tax math changes the picture — pretax HSA dollars for medication effectively give you a 22-32% discount depending on your marginal bracket. Model your total contributions and expected drug spend with the HSA vs FSA Calculator.

Three fast checks before you conclude the drug is out of reach:

• Confirm the fair reference cash price in your area using the Drug Cost Finder. If the pharmacy you were quoted is dramatically above local benchmarks, changing pharmacies alone may cut your cost in half.
• Model your total year of health costs — deductible, coinsurance, HSA contribution, and GLP-1 out-of-pocket — under both your current plan and a plausible alternative at open enrollment (starting November 1, 2026) using our Plan Cost Calculator.
• If you have a related procedure planned (bariatric consultation, sleep study, cardiology workup), price-check it with the Procedure Cost Finder so the diagnostic that supports your PA doesn't itself blow up your year.

GLP-1 coverage on employer and private insurance in 2026 is narrower than the headlines suggest — 36% of employer plans, tighter after January 1, more restrictive prior authorization requirements, and increasingly aggressive reauthorization at the 6- or 12-month mark. But the coverage that does exist is largely accessible with the right documentation, and the coverage that does not can often be reached under a non-excluded FDA indication (sleep apnea, cardiovascular risk reduction, type 2 diabetes) rather than the weight-loss indication.

Seven-step action list: (1) triage exclusion vs prior authorization by reading the SPD and calling the PBM; (2) build the PA package with BMI, comorbidity, and prior weight-management documentation; (3) if excluded, submit under a qualifying non-weight-loss indication if one applies; (4) file a formulary exception if step therapy or tiering is in the way; (5) if denied, file the internal appeal with a clinical letter, guideline citations, and a same-specialty peer-to-peer request; (6) escalate to external review (fully insured) or DOL EBSA (self-funded ERISA) if internal appeal fails; and (7) bridge with manufacturer direct-to-consumer pricing during the appeal so momentum does not break. Well-documented appeals succeed roughly 60% of the time. The documentation is the entire fight.